News – Page 433 – Endpoints News

MarketingRx roundup: Moderna clues in to ‘Jeopardy’; BMS, Gilead build out clinical trial diversity program

3 years ago

Betting on CD47 as others ditch the target, ALX borrows up to $100M to push sole clinical drug forward

3 years ago

Covid-19 continues to befuddle Big Pharma as AbbVie axes PhI of an oral drug

3 years ago

Updated: Samsara backs ex-Gilead duo's amalgamation of NASH, liver drug assets from former employer, other biopharmas

3 years ago

Updated: Eli Lilly blames Biden's IRA for cancer drug discontinuation as the new pharma playbook takes shape

3 years ago

JP Morgan splashes into the life sciences, tapping Stephen Squinto to run venture team with high-powered advisors

3 years ago

Covid-19 spurred a historic vaccine R&D effort. What does it mean for future pandemics?

3 years ago

Pfizer declares 'first-ever' PhIII win for RSV vaccine in infants — and it's steering straight to FDA

3 years ago

A single injection of Unity's anti-aging hypothesis bears fruit in PhII, as pivotal plans shape up

3 years ago

Drew Armstrong is coming to Endpoints(!) And there are some more surprises to come

3 years ago

That secretive ARCH biotech with two antibodies from MorphoSys? It’s now got $120M

3 years ago

#CPHI22: Endpoints sits down with conference exec as the manufacturing world says ‘Guten Tag’ to CPHI

3 years ago

#CPHI22: Contract manufacturers will still be navigating global challenges into next year

3 years ago

#CPHI22: Annual report shows ‘moderate outlook’ and focus on mRNA

3 years ago

#CPHI22: A look back at the biggest manufacturing projects in 2022

3 years ago

#CPHI22: Cell and gene manufacturing expected to see a bump as it moves out of the pandemic

3 years ago

#CPHI22: Supply chain woes are still bearing down on manufacturers

3 years ago

Bristol Myers' blockbuster-to-be Reblozyl scores a PhIII win

3 years ago

Daiichi Sankyo sets new highs for AstraZeneca-partnered cancer drug Enhertu

3 years ago

FDA to kick off CMC readiness pilot program next April

3 years ago

AbbVie puts up fight against Orilissa generics from Sandoz, Teva and others

3 years ago

Under hub-and-spoke biotech, serial founders launch new startup hoping to make gene therapies for the eye

3 years ago

Thermo Fisher wagers on early cancer diagnostics in $2.6B cash deal for multiple myeloma test maker

3 years ago

Intrinsic wanted an IPO. Instead, it's a SPAC for the gut-brain microbiome biotech

3 years ago

First page Previous page 430 431 432433434 435 436 Next page Last page